杂质
化学
指南
生化工程
药品
纳米技术
工艺工程
有机化学
材料科学
工程类
药理学
医学
病理
出处
期刊:Current Pharmaceutical Analysis
[Bentham Science]
日期:2020-07-11
卷期号:17 (8): 960-968
被引量:12
标识
DOI:10.2174/1573412916999200711151147
摘要
Backgroun: Metallic impurities are the traces of metals that can be found in finished drug products. Description: These metallic impurities in pharmaceutical preparations can enter from formulation ingredients, catalysts, and process equipment, containers and closures. They are not completely removed from the product by practical manufacturing techniques and should be evaluated relative to safetybased limits. They can affect drug efficacy or produce direct toxic effect on the patient. Methods: In this paper, an attempt has been made to review these metallic impurities including potential sources and analytical procedures to quantify these impurities. ICH guideline on these impurities and measures to control impurities has also been discussed in the paper. Results: The implementation of ICH Q3D guideline with the quality risk assessment approach is an important milestone to harmonize control of elements worldwide. Conclusion: This approach allows manufacturers to provide vital information about the contribution of impurities in the drug product.
科研通智能强力驱动
Strongly Powered by AbleSci AI